Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults

This Phase 1 study is testing a new type of cell therapy called CAR-T cells in children, teenagers, and young adults with acute lymphoblastic leukemia (ALL) that has come back or stopped responding to standard chemotherapy. **You may be eligible if...** - You have B-cell or T-cell ALL that has relapsed (come back) or is refractory (not responding) to standard chemotherapy - No other standard curative treatment is available - You would be eligible for a stem cell transplant if the CAR-T treatment achieves remission - Your performance score indicates you are well enough to participate - Your life expectancy is at least 12 weeks **You may NOT be eligible if...** - Your leukemia has not been refractory or relapsed - You are not eligible for a stem cell transplant - You have conditions that would make CAR-T cell therapy unsafe - For the T-cell leukemia arm: there is no suitable matching donor available Talk to your doctor to see if this trial is right for you.